Editorial
doi: 10.1080/14656566.2022.2122710.
Epub 2022 Sep 14.
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
Affiliations
- PMID: 36104973
- DOI: 10.1080/14656566.2022.2122710
Item in Clipboard
Editorial
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
Expert Opin Pharmacother.
2022 Sep.
No abstract available
Keywords: C5; FcRn; Myasthenia gravis; biological drugs; immunosuppression; monoclonal antibodies.
Comment in
-
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis.Expert Opin Pharmacother. 2023 Apr;24(5):665. doi: 10.1080/14656566.2023.2192867. Epub 2023 Mar 21. Expert Opin Pharmacother. 2023. PMID: 36927370 No abstract available.
Comment on
-
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.Neurotherapeutics. 2022 Apr;19(3):897-910. doi: 10.1007/s13311-022-01181-3. Epub 2022 Feb 14. Neurotherapeutics. 2022. PMID: 35165857 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
